Introduction
There are a variety of non-replicating and self-replicating viral-based vector delivery systems under consideration for long-term gene replacement therapy. Non-replicating vectors require chromosomal integration, while self-replicating vectors are maintained extrachromosomally. Most of the vectors used currently in gene therapy clinical trials are non-replicating types generated from the essential components of retrovirus, adenovirus, or adenoassociated virus. 1 Although these vectors show great promise, they have limitations. [2] [3] [4] [5] Self-replicating viral-based vectors are capable of longterm episomal persistence in mammalian cells. 6, 7 These vectors contain components derived from (1) EpsteinBarr virus (EBV; oriP/EBNA1 viral elements); [8] [9] [10] (2) bovine papilloma virus (BPV-1; ori elements); 11, 12 ( 3) genomic components from either yeast (YACs) or human chromosomes (HACs); [13] [14] [15] [16] and (4) chimeric viral/genomic systems either engineered from the oriP/EBNA1-based pLIB or from mammalian artificial episomal chromosomes (MAECs). [17] [18] [19] The advantages and limitations of these various viral vector-based systems in biological research are discussed elsewhere. 7 However, episomal vectors are being considered for use in human gene therapy. [20] [21] [22] [23] [24] Of these, the EBV-based vectors may have several distinct advantages. EBV is a human gammaherpesvirus with a 172-kb double-stranded DNA genome that preferentially infects Blymphocytes and some epithelial cells, although it has been detected in other tissues. 7 Establishment of EBV requires just two viral encoded components, the latent origin of replication (oriP) and its trans-activating protein (EBNA1). 25, 26 About 90% of the world's adult population is estimated to be infected with non-symptomatic EBV infection. Engineered EBV-based oriP/EBNA1 vectors persist in the nucleus of target cells as multi-copy episomes. They are capable of inserting a gene of interest that cannot be interrupted or subjected to regulatory constraints arising from chromosomal integration. They also have a low mutation rate, ie less than 10 5 , and tend not to rearrange. 27, 28 Use of EBV-based vectors have been shown to result in a higher transfection efficiency than the use of chromosome-integrating plasmids. 29, 30 Finally, EBV-based vectors can be designed to shuttle between eukaryotic and prokaryotic cells allowing for the transfer of very large genomic fragments of DNA. 9, 31 Historically, EBV infection appeared to be limited to only primate cells having failed to replicate in hamster and mouse cells. 18, 32 However, shortly thereafter, small EBV shuttle vectors were reported to replicate in rat PC12 cells and mouse fibroblastoid cell line. 19, 33 More recently, EBV-based vectors of >30-kb have been reported to replicate in mice. 34, 35 Although these reports are encouraging, these EBV-based vectors were not tested at delivering large (>100 kb) intact human gene loci.
As discussed in this paper, we developed a novel 'second-generation' non-infectious and non-transforming Gene Therapy EBV-based vector capable of shuttling between prokaryotic, human and mouse cells. This vector carries the entire 185-kb human ␤-globin gene loci and transcribes correctly spliced human ␤-globin transcript. We were able to consistently isolate episomes from all transfected cell cultures, regardless of selective pressure for 3 months (the duration of the experiment). We calculated a very high episome retention rate of 93% in transfected EBNA1-negative murine cells, regardless of selective pressure as well. These results illustrate the potential of an EBVbased vector to deliver and maintain the large and intact human gene loci necessary for successful human gene therapy.
Results

Stable transfection of human DR and mouse A9 cells
The episomal vector (pBH148, Figure 1 ) used in this study was initially generated as previously described and is equipped with the entire 185-kb human ␤-globin gene locus. 10 In addition, the plasmid carries the two essential EBV elements oriP and EBNA1 which are required for latent episome replication and replication initiation, respectively.
To assess the transfection efficiency of pBH148 in the EBNA1-negative murine A9 cells (A9pBH148), we also co-transfected EBNA1-expressing human DR cells (DRpBH148). This EBV-permissive positive cell line was chosen because it has been used previously by our laboratory to establish stable clones carrying large pBR322-based vectors (up to 350-kb) of anonymous human genomic inserts. 7, 10 Approximately 40 A9pBH148 clones/10 6 transfected cells and 50 DRpBH148 clones/10 6 transfected cells were obtained yielding similar transfection efficiencies. All experiments described below were performed on the pooled clones. The clones were maintained under hygromycin selection for 1 month before experimentation. After 1 month under selection, 6 × 10 8 cells were lysed and the episomal pBH148 DNA was isolated. The episome integrity was assessed by agarose gel electrophoresis and subjected to PCR using hygromycin specific primers (Figure 2 ). For this experiment, we used bacteria propagated pBH148 as a positive control. Lanes 2, 3 and 4 were all positive for the hygromycin resistance gene on pBH148. Lanes 6 and 7 (background negative control lanes) were included to rule out any nonspecific primer amplification in either A9 or DR genomic DNA. These results demonstrated that the hygromycin sequence on pBH148 was only amplified from the transfected cell lines as expected.
Long-term stability of pBH148 in A9 cells
To test the stability of pBH148 episomes in the murine A9 cells over time, the A9 cell transformants were split into two separate cultures, one maintained with hygromycin selection and one without. These cultures were cultivated concurrently for a period of 3 months (length of the experiment). For comparison, the stably transfected DRpBH148 cell culture was maintained under selection for the same period of time and analyzed in parallel.
Pure unadulterated stable circular double-stranded episomal pBH148 (totally free of genomic DNA) was guaranteed by the episomal preparation. To ensure episome purity, we loaded the DNA on a 0.8% agarose 35-cm gel ( Figure 3 ). The 200-kb circular double-stranded pBH148 episome migrated much slower than any other DNA fragments (Ͻ25-kb), including any linear fragments of pBH148 accidentally generated by mechanical shearing during the preparation. Although the episomal preparation developed by our laboratory consistently isolates large circular double-stranded plasmids, we have reported shearing and linear fragments before. 10, 26, 36 However, on three separate occasions, our laboratory demonstrated by FISH analysis that the large EBV-based episomal vectors did not integrate. 10, 19, 36 In support, this study shows conclusively that circular double-stranded pBH148 episomes were extracted from the late-passage A9pBH148 cells in a similar manner as those isolated from the late-passage DRpBH148 positive control culture by agarose gel electrophoresis and Southern blot hybridization ( Figure 3 ). The blot was probed with an AlfIII-digested pBH140 vector that was used to generate the 200-kb pBH148. 10 All the A9pBH148 episomes iso- lated from any culture to week 12 (lanes [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] migrated at approximately the same position as the episome from the positive control DRpBH148 (lane 1). A DNA ladder, from the ethidium bromide-stained gel, is superimposed on the Southern blot to illustrate the distances between the intact 200-kb pBH148 circular episome, any sheared linear pBH148, and genomic fragments. Surprisingly, the intensity of the episome signal is very consistent between weekly episomal preparations, regardless of selective pressure, and intensity is still strong at week 12, even without selection. These results are indicative of stable pBH148 episomal maintenance. In addition, the genomic region on the blot (~25-kb) did not hybridize at all. This supports our assertions that (1) a carefully performed episomal preparation results in mostly large circular episomes with very little DNA shearing; and (2) the very presence of 200-kb circular DNA and the lack of any signal elsewhere in the blot guarantees that pBH148 did not integrate into the host chromosomes.
pBH148 long-term persistence over a period of time
In vitro functional and therapeutic studies with transfecting DNA are usually performed using cell cultures maintained under marker selection. Therefore, A9pBH148 cul- Gene Therapy tures were grown continuously for 3 months with and without hygromycin selection in the medium and passaged twice a week at 1/10 dilution. This culture regimen corresponds to approximately 15 cell doublings every 2 weeks, for a total of 90 doublings. Episomes extracted from these late-passage cultures were analyzed by Southern blot hybridization as mentioned above. Although the persistence of pBH148 episomes was evident (Figure 3 ), we were interested in evaluating the retention rate of the pBH148 episome in the EBNA1-negative A9 cells with and without hygromycin selection as a function of time. Therefore, episomal DNA was isolated at the indicated time points (Figure 4 ) and qualified by agarose gel electrophoresis followed by Southern blot using the AlfIII digested pBH140 as described. 19 The values from the blot was then assessed by phosphoimaging (Figure 4) . Strikingly, pBH148 is very stable in the EBNA1-negative A9 cells even without selection. The plot highlights an episome retention rate greater than 93%. The plot also indirectly confirmed that pBH148 was maintained as an episome in the A9 cells and has not integrated because some signal loss occurred. Specifically, the episome signal decreased from the actively dividing A9 cells with and approximate half-life of 15 days. Given a 24-h doubling time for A9 cells, this rate corresponds to a 93% efficiency of episome retention per cell division. 19, 31 We know that the viral encoded trans-activator protein, EBNA1, is absolutely required for replication of an oriPbased plasmid in human cells and may be required for episomal maintenance in nonpermissive cells (unpublished results). DR fusion cells endogenously express EBNA1 and maintain an oriP-based plasmid in the absence of selection. It was important to prove that the A9 cells did not express any endogenous EBNA1 protein. Indeed, EBNA1 was detected by PCR in all the untransfected DR cell preparations, regardless of selection ( Figure 5 ). More importantly, EBNA1 was not detected in the untransfected A9 cell preparations and was detected in all the A9pBH148 transfected cell cultures, regardless of selection. EBNA1 binds as a homodimer to two locations within the oriP: (1) the family of repeats (FR) is necessary for nuclear retention and episome segregation; and (2) the dyad of symmetry (DS) is needed for replication initiation. Interestingly, previous studies demonstrated that oriP does not function in rodent cells. 18, 25 In contrast, it was shown that a 170-kb full-size EBV genome can stably replicate as a circular double-stranded episome in murine cells. 19 Therefore, EBV may have evolved an alternative origin of replication, distinct from oriP. In support, one such site was recently mapped. 37 However, pBH148 has only two EBV-derived genes (oriP and EBNA1) and does not have this presumed origin. We believe that replication initiation of pBH148 may be occurring at the origin site recently mapped within the inserted human ␤-globin locus. 38 Admittedly, this is difficult to prove under the conditions of this study. However, even though A9 cells are incapable of maintaining an oriP/EBNA1-based episome without selection, our study suggests (1) the stability of a large 200-kb EBV/BAC-based episomal vector in mouse A9 cells; and (2) the potential utility of the human ␤-globin locus origin in maintaining this type of episome in nonpermissive EBNA1-negative A9 cells.
Figure 3 Episomal analysis of the oriP/EBNA1-based vector in EBNA1-
Persistent human ␤-globin transgene expression in nonpermissive A9 cells
RT-PCR using specific primers flanking intron 2 was applied to test potential transgene expression from the human ␤-globin gene cluster on the pBH148 vector in the stably transfected murine A9 cells ( Figure 6 ). The untransfected A9 negative control cells did not transcribe any human ␤-globin gene product (lane 15). However, RT-PCR on the total RNA prepared from the A9pBH148 cells generated the unique 231-bp ␤-globin gene product regardless of selective pressure (lanes 2-12) and is identical in size to that obtained from the permissive DRpBH148 positive control total RNA prep (lane 13). In addition, no other product was detectable (data not shown) including the approximately 1-kb fragment that would be generated from unspliced DNA contamination (data not shown). Thus, all primary transcripts made on the human ␤-globin genomic template were correctly spliced, at least across this intron 2. 39 This observation verified sustained human ␤-globin transcription from a stably maintained extrachromosomal episome during prolonged in vitro cell culture in a murine A9 cell line without selective pressure. Hence, this study shows similar persistent transcriptional activity of the human 
The correctly spliced transcript of 231-bp is evident in all transfected A9pBH148 cultures with (+) or without (Ϫ) selection (lanes 2-11) as it was in the transfected DRpBH148 cultures with (+) and without (Ϫ) selection (lanes 12-13). No primary transcript was detected in either the negative control (lane 14) or the A9 cells alone (lane 15).
␤-globin gene locus in murine A9 cells as was previously demonstrated in permissive human DR cells. 10 
Discussion
The present study demonstrates the relevance of an oriP/EBNA1-based episomal vector to deliver and transcribe human therapeutic genes from a stably maintained episome in EBNA1-negative murine cells. The episomal vector, pBH148, used in this research project was generated by combining the bare essential components of the latently episomal human herpes virus type 4 EpsteinBarr virus (EBV), some specific BAC elements, and an entire 185-kb human ␤-globin gene locus, including the locus control regions. Propagation in bacteria did not result in any unwanted methylations and stable transfection occurred in both late-passage cultured human EBNA1-expressing DR fusion cells and EBNA1-negative murine A9 fibroblast cells.
Stable episomal persistence of pBH148
The criteria used to demonstrate episomal maintenance in this study is based on episomal preparation of stably transfected cultured eukaryotic cells and the relative migration rate of the recovered circular double-stranded DNA as analyzed by agarose gel electrophoresis. This method was employed previously for the rapid and accurate identification of plasmids up to 350-kb. 36 Indeed, we were able to show conclusively that the 200-kb circular double-stranded pBH148 episome was isolated from both the permissive DR human cells and the nonpermissive A9 murine cells, regardless of selective pressure for the length of the experiment. However, this is not the first time human DNA has been maintained extrachromosomally in rodent cells. YACs, with up to 1500-kb of human DNA, replicated as episomes in mouse cells following yeast spheroplast fusion, but were unstable in the absence of selective pressure. 13, 14, 40, 41 Although these YACs contained large human DNA fragments (complete with replication origins) they were devoid of any segregation apparatus. In other experiments, use of microcell fusion demonstrated that as little as 100-kb of human DNA could be maintained episomally in EBNA1-expressing mouse cells in low copy number, presumably by EBNA1 protein binding to the oriP on these vectors. 4, 19, 42 In addition, oriP-based plasmids with up to 30-kb of random DNA insert were maintained extrachromosomally in EBNA1-expressing hamster cells, but the episomes were rapidly lost from these rodent cells when selection was removed. 18, 43 We believe that these experiments demonstrate the necessity of both endogenous expressed EBNA1 and selective pressure for an oriP/EBNA1-based plasmid to be maintained episomally in rodents. Ideally, oriP is bound by EBNA1 at the family of repeats (FR) and the dyad of symmetry (DS). EBNA1 binding to FR is absolutely required for episome segregation, while EBNA1 binding to DS initiates episome replication. We postulate that the FR segregation function of oriP is ubiquitous in nature, while the DS initiation of replication function of oriP may be species-specific or is inactive in the mouse. We base this assumption on the extensive research conducted in our laboratory demonstrating that oriP-based plasmids devoid of DS are lost more quickly than oriP-based plasmids devoid of FR in rodent cells (unpublished results). Therefore, we feel a ubiquitous mammalian origin may be required if oriP-based plasmids are to be used in rodent disease models. Consequently, pBH148 was engineered with an entire human ␤-globin locus, including a well-studied and fully mapped mammalian origin. 44 We believe our results suggest that the human ␤-globin origin may be complementing an inactive oriP. Admittedly, we could strengthen this argument by testing a pBH148 episome devoid of a ␤-globin gene origin, but (due to our laboratory closure) we were unable to continue this work. However, in this study large circular double-stranded episomes were clearly isolated from EBNA1-negative nonpermissive murine A9 cells, regardless of selective pressure. Furthermore, since pBH148 constitutively expresses EBNA1, it is not restricted to cells expressing a pre-established EBNA1 gene as needed in previous studies. [45] [46] [47] Human ␤-globin transgene expression The procedure used to verify large circular doublestranded episomes from the pBH148 transfected cell cultures as described above will not necessarily detect small sequence alterations or minor rearrangements within the vector. It has been shown that rearrangements of any kind in the ␤-globin gene locus, especially in the DNase hypersensitive sites within the LCR, usually silences gene expression. 41 In fact, recent approaches to overcome gene silencing include either lentivirus-encoded 'shaveddown' ␤-globin gene locus transcription units or circumvention of the ␤-globin gene locus entirely by erythropoietin delivery in myoblasts, by electrotransfer, and by adeno-associated virus gene transfer. [48] [49] [50] [51] [52] Although these approaches have had limited success, there remain unresolved safety issues using lentivirus and adeno-associated virus in human applications. In addition, there are concerns about encapsulated myoblast technology and longevity, as well as the cost and efficacy of repeated electrotransfers of erythropoietin in diseased humans. All previous cases of de novo activation of globin gene expression in vivo or in vitro involved an erythroid genetic background. 53 Intriguingly, transcription of the nonintegrated ␤-globin gene occurred in non-erythroid human cells. The authors proposed that transfection of large genomic fragments as self-replicating naked DNA in somatic cells may allow basal transcription before Gene Therapy nucleosome repression. 10 Once a transcriptionally active chromatin has been established, autonomous replication may preserve its stable inheritance in dividing cells. 54, 55 Clearly, the generality of this phenomenon must be tested, particularly in vivo on animal disease models.
In the present study, we demonstrate stable transgene transcription of the human ␤-globin gene by RT-PCR in both late-passage permissive DR and nonpermissive A9 cell cultures. Furthermore, no human ␤-globin transgene transcription of any type was detected in untransfected cells, indicating that all primary transcripts originated from the pBH148 episomal vector.
Potential of double-stranded circular oriP-based vectors
With the exception of phenotypic rescue of the beige mutation by circular episomal YACs in mouse cells, stable disease complementation by vectorology in human cells has yet to be accomplished. 40 This and two previous studies demonstrated that large virus-based circular therapeutic episomes might soon become a reality. 8, 19 In addition, initial research using oriP/EBNA1-based 'mini-EBV' vectors led to the generation of an enhanced EBNA1 variant capable of improved episomal maintenance and transgene expression by a new improved second generation mini-EBV-based vector. 9, 10, 26 These vectors have been used for in vitro phenotypic correction of B cell lines by transduction of cDNAs coding for X-linked LeschNyhan syndrome and the severe hereditary Fanconi's anemia complementation group C. 31, 36 In other studies, EBV-based vectors have been used to express cytokines, growth factors, and human collagen V. [55] [56] [57] Use of oriP/EBNA1-based episomal vectors can potentially revolutionize basic chromosome research ranging from function and gene expression to transgene production of therapeutics to somatic/germline gene therapy. This study adds to the growing list of specialized gene transfer and expression systems derived from EBVbased plasmids. EBV-based episomal vectors allow for extrachromosomal maintenance of full-size human genes eliminating genomic position effects and reducing the potential long-term pathological consequences due to irreversible genetic modifications of the genome as seen when integrative vectors are used. 7 In addition, episomes can be used for gene therapy that rely on ectopic genomic activation on episomes as an alternative strategy for syndromes recalcitrant to stable phenotypic correction by cDNA expression. We believe the research presented here illustrates a suitable gene transfer system that transfects mammalian cells ubiquitously, displays stable episomal replication, and fully expresses a transgene over extended periods of time.
Methods and materials Preparation of the oriP/EBNA1-based pBH148
The episomal vector used in this study (Figure 1 ) was generated as previously described. 10 Briefly, a 185-kb human ␤-globin genomic clone was obtained from a human genomic library and ligated to the alkaline phosphatase-treated oriP/EBNA1-based plasmid, pBH140 (not shown), engineered in our laboratory. The only difference between pBH140 and pBH148 is the presence of the 185-kb human gene insert.
Circular double-stranded episomal pBH148 was pur-ified from a (shaken) 2-liter overnight culture of transformed Escherichia coli (DH5␣) cells using Qiagen columns (Chatsworth, CA, USA). Eluted episomal DNA was quantified by fluorescent spectroscopy (DynaQuant, Amersham Sciences, NJ, USA) and adjusted to 10 g/l in sterile Tris-HCl (pH 8.0). Episomal integrity was assessed by agarose gel electrophoresis.
Cell transfections
For transfections, column purified episomal pBH148 was diluted as recommended (Promega Transfection Guide, WI, USA). Human DR positive control cells and mouse A9 cells (ATCC) were plated in a treated 12-well culture plate (Corning, Costar, MA, USA). Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10% fetal calf serum (FCS) was added and the cells incubated in a humidified 5% CO 2 chamber at 37°C until they were approximately 60% confluent (2 days). Lipofection was carried out according to the manufacturer's protocol (GIBCO, BRL, NY, USA) with a few modifications. Briefly, concentrated episomal pBH148 was added to a 1.5 ml tube containing 150 l DMEM (with neither serum nor antibiotics) and 20 l Lipofectamine Plus reagent to obtain DNA g concentrations of 0.0, 0.1, 0.25, 0.5 and 1.0. The mixture was incubated for 15 min at room temperature. 8 l of Lipofectamine reagent was added and the tube incubated as before. Cell cultures were rinsed with sterile phosphate buffered saline (PBS) before transfection. After transfection, 0.75 ml of DMEM supplemented with 10% FCS was added and the plate incubated as before for 5 h. Following incubation, 1 ml of DMEM (supplemented with 10% FCS, 1 × penicillin/streptomycin, and L-glutamine; Gibco) was added and the cells incubated for 2 days as before. Medium was changed on day 3 and every 2 days thereafter for 1 week with complete DMEM supplemented with 200 g/ml hygromycin (DR) and 700 g/ml (A9) for selection of pBH148. After 1 week, the surviving DR and A9 cells (from the 1.0 g and 0.5 g wells) were trypsinized, plated separately into 25-cm 2 flasks (Costar), and grown to confluency under selection. Cells were split as needed into 75-cm 2 flasks (Costar) under selection for 1 additional month. After verification of pBH148 DNA by PCR, the A9pBH148 culture was split into two 225-cm 2 flasks (Costar). The cultures were grown to confluency and split as needed. In this experiment, less than 10% of the confluent culture seeded the new culture guaranteeing that episomal pBH148 correctly segregated to daughter cells during replication. The cultures were grown with and without hygromycin selection for a period of 3 months changing the medium as needed (about every 3rd day). The DRpBH148 was split similarly to the A9pBH148 culture, but it was maintained under hygromycin selection only. In addition, untransfected DR cells and untransfected A9 cells, under hygromycin selection, expired within 9 days, while the same cells without selection survived for the length of the experiment.
Episomal preparation of transfected pBH148 in A9 and DR cells
Episomal gels: Circular double-stranded episomal pBH148 DNA was isolated from 6 × 10 8 stably transformed cells as previously described with some modifications. 7 Briefly, cells were lysed in a solution of 50 mM PCR: A hygromycin fragment of 431-bp was detected in the 1-month-old DRpBH148 and A9pBH148 cell cultures, maintained under selection, by the polymerase chain reaction (PCR). PCR conditions were for 30 cycles: 93°C, 65°C, and 72°C for 30 s each without either an initial hot start or a final extension, using forward 5Ј-CGTCTGCTGCTCCATACAAGCC-3Ј and reverse 5Ј-TGCCTGAAACCGAACTGCCC-3Ј primers specific for the hygromycin selection gene on pBH148. Each reaction was in a volume of 25 l with 10 g of episomally prepared DNA following standard protocol (Promega).
An EBNA1 fragment of 227-bp was detected in all the late-passage DRpBH148, A9pBH148, and in the DR background positive control. However, EBNA1 was not detected in the A9 cell cultures by PCR verifying their EBNA1-negative condition. PCR was carried out using the conditions described above using forward 5Ј-GGAAGCTTGGAAAGCATCGTGGTC-3Ј and reverse 5Ј-ATGGATCCAAAGGGGAGACGACTCA-3Ј EBNA1 specific primers.
Southern blot and episomal persistence
In preparation for alkaline transfer, the ethidium bromide-stained episomal gel was immersed in 0.25 M HCl for 30 min to fractionate the large circular doublestranded pBH148 episomal DNA. The gel was rinsed briefly in sterile water and placed in a 0.5 M NaOH/1.5 M NaCl alkaline solution for 2 h. DNA was transferred to a prewetted Magnagraph nylon membrane (MSI, MI, USA) by overnight capillary action in new alkaline solution. The membrane was rinsed briefly in sterile water for 30 s and DNA was UV crosslinked to the nylon using the automatic crosslink cycle on a UV Stratalinker 1800 (Stratagene, La Jolla, CA, USA) at 1200 joules × 100. During the transfer, an AflIII digested pBH140 probe was labeled with 50 CIF ␣ 32 P duct according to Prime-AGene kit protocol (Promega). The membrane was prehybridized in 10 ml preheated UltraHyb (Ambion, TX, USA) for 30 min at 42°C. Labeled probe was well mixed into the prehybridization solution and incubation continued overnight at 42°C. After the hybridization solution was removed, the blot was washed twice at room temperature for 5 min each in 2 × SSC/0.1% SDS then twice for 15 min each in 0.1 × SSC/0.1% SDS. The rinsed blot was wrapped in cellophane, placed in a cassette equipped with an intensifying screen, and exposed to X-OMAT AR film (Eastman Kodak, NY, USA) at Ϫ80°C for 60 min. The film was processed in a Konica SRX 201A automatic developer (Tokyo, Japan) and photographed.
RT-PCR
Transgene expression of the human ␤-globin gene was analyzed by reverse transcription-based polymerase chain reaction (RT-PCR). Total cellular RNA was isolated following the manufacturer's protocol (RNAqueous, Ambion) from all stably transfected DRpBH148 cells, A9pBH148 cells, DR cells and A9 cells. The RNA was resuspended in 250 g/l aliquots and stored at Ϫ80°C until needed. RT-PCR was carried out using Superscript One-Step with platinum Taq (Gibco) following this thermo cycling profile: 50°C for 30 min (cDNA synthesis), 94°C for 2 min (reverse transcriptase denaturation), and 40 cycles of: 94°C, 65°C, 72°C for 30 s (PCR). Forward 5Ј-GGACCCAGAGGTTCTTTGAGTCC-3Ј and reverse 5Ј-GCACACAGACCAGCACGTTGCCC-3Ј primers specific for the human ␤-globin gene region located in exons 2 and 3 were used. A product of 231-bp and 1-kb is generated from correctly spliced human ␤-globin RNA transcript and unspliced DNA, respectively.
In memoriam: Jean-Michel Vos
We are saddened by the death of Jean-Michel Vos on 31 November 2000, who succumbed to cancer at the early age of 44 years. Jean-Michel came to the University of North Carolina in 1987, where he was an active member of the Department of Biochemistry and Biophysics, the Lineberger Comprehensive Cancer Center, the Program in Molecular Biology and Biotechnology, and the Curriculum in Genetics. He was internationally recognized as an expert in the field of artificial chromosome technology and gene therapy in which he was a pioneer. JeanMichel will not only be missed as a scientist, but also as a fun-loving and good human being. He was committed to his family -his wife Eliane and his two daughters Natasha and Olivia. He left us too soon and I am honored to have known him. He will be missed by all of us in the Vos laboratory.
